1. Home
  2. LDI vs PRTA Comparison

LDI vs PRTA Comparison

Compare LDI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

N/A

Current Price

$0.87

Market Cap

542.4M

Sector

Finance

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.03

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LDI
PRTA
Founded
2010
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.4M
449.7M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
LDI
PRTA
Price
$0.87
$9.03
Analyst Decision
Sell
Buy
Analyst Count
3
9
Target Price
$3.00
$19.00
AVG Volume (30 Days)
2.8M
471.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
N/A
$814,000.00
Revenue This Year
$17.58
$1,111.38
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
$35.73
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$7.73
52 Week High
$5.05
$11.80

Technical Indicators

Market Signals
Indicator
LDI
PRTA
Relative Strength Index (RSI) 37.79 51.70
Support Level $0.83 $8.91
Resistance Level $1.22 $9.36
Average True Range (ATR) 0.08 0.41
MACD -0.00 0.05
Stochastic Oscillator 12.37 70.19

Price Performance

Historical Comparison
LDI
PRTA

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: